2 PAM Autoinjectors
ID: 2-PAM-BARDAType: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

Original Source

https://sam.gov/opp/028451b7e45b4bcab1eb112d1934f2f5/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking market information regarding the development and manufacturing of 2-PAM (Pralidoxime) autoinjectors intended for the treatment of organophosphate poisoning, including exposure to nerve agents. The objective is to gather data on the capabilities of businesses to produce FDA-approved autoinjectors, with a requirement to manufacture up to 2 million units that meet Emergency Use Authorization standards by 2027. This initiative is crucial for ensuring effective public health responses to chemical, biological, radiological, and nuclear (CBRN) threats through adequate medical countermeasures. Interested parties must submit their responses, including business and technical representations, by May 14, 2025, and can contact Kevin Dean at kevin.dean1@hhs.gov or Erin Greninger at erin.greninger@hhs.gov for further information.

    Point(s) of Contact
    Kevin Dean, Contracting Specialist
    (202) 989-5371
    kevin.dean1@hhs.gov
    Erin Greninger, Contracting Officer
    (771) 210-7767
    erin.greninger@hhs.gov
    Files
    Title
    Posted
    SSN 2-PAM BARDA Autoinjectors.pdf
    The Sources Sought Notice (SSN No. 2-PAM-BARDA) is issued by the Biomedical Advanced Research and Development Authority (BARDA) to collect information on the market capabilities for developing and manufacturing 2-PAM (Pralidoxime) autoinjectors intended for the treatment of organophosphate poisoning, including exposure to nerve agents. This notice is for market research purposes only and does not constitute a contract award. BARDA seeks input from both small and other than small business entities regarding their capacity to produce FDA-approved autoinjectors capable of fulfilling Emergency Use Authorization standards by 2027. Key requirements include the ability to manufacture 2 million units and meeting FDA reliability standards. The notice details specific guidelines for submitting business and technical representations, emphasizing the necessary qualifications, prior experience, and technical capabilities. Responses are required by May 14, 2025, and include important regulatory information concerning ongoing development and manufacturing capabilities. Overall, this SSN aims to enrich BARDA's planning for potential acquisitions while ensuring effective public health responses to CBRN threats through adequate medical countermeasures.
    Lifecycle
    Title
    Type
    2 PAM Autoinjectors
    Currently viewing
    Sources Sought
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The initiative aims to enhance public health preparedness by fostering partnerships with private organizations, government laboratories, and academic institutions to expedite the development of life-saving MCMs critical for national health security. Proposals will be evaluated based on scientific merit, technological maturity, and regulatory compliance, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties should direct inquiries to BARDA-BAA@hhs.gov for further information.
    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.
    JPEO-CBRND RFI - Innovation in Biologics Manufacturing
    Dept Of Defense
    The Department of Defense, through the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), is issuing a Request for Information (RFI) focused on innovations in biologics manufacturing. This RFI seeks information on capabilities and technologies related to biologics manufacturing, specifically targeting cell-free production capabilities, advancements in process control, and methods to expedite drug substance release. The initiative aims to enhance medical solutions for crisis response and improve preparedness against future threats. Interested parties are encouraged to share their capabilities via the Joint Enterprise Technology Tool (JETT) platform, with no commitment from the government to issue a subsequent Request for Proposal (RFP).
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative research to enhance public health preparedness against various biomedical threats. The initiative encompasses multiple Areas of Interest (AOIs), including the development of medical countermeasures for emerging infectious diseases, repurposing existing drugs for chemical threats, and advancing technologies for at-home diagnostics. Interested parties must have active registration with SAM.gov and are encouraged to engage in pre-submission consultations; abstract submissions are due by specified deadlines, with funding amounts contingent on the quality of proposals and alignment with program goals. For further inquiries, interested vendors can contact the BARDA DCMA DRIVe Team at DRIVeAcquisitions@hhs.gov.
    J&A Procurement of Smallpox (Mpox) Vaccine for the Strategic National Stockpile
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to procure additional doses of the JYNNEOS™ vaccine for the Strategic National Stockpile in response to the ongoing monkeypox outbreak. The procurement aims to rapidly secure 11 million doses of the vaccine by utilizing existing bulk drug substance and to enhance manufacturing capacity through technology transfer to contract manufacturing organizations. The JYNNEOS™ vaccine is critical as it is the only licensed vaccine for both smallpox and monkeypox, making it essential for public health preparedness. Interested parties can contact Yifan Yang at yifan.yang@hhs.gov, with the total estimated value of the contract modification being $992,400,000.
    BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is conducting market research for the development of a barrier combination product aimed at preventing and treating battlefield wounds and subsequent infections. This initiative, part of the Battlefield Wound Infection Prevention and Treatment (BWI P&T) program, seeks to identify commercial solutions that can effectively address the unique challenges of wound care in austere environments, where medical resources may be limited. The barrier combination product is expected to play a crucial role in a Family of Systems (FoS) approach, providing innovative solutions for both military and commercial applications in wound care. Interested parties are invited to submit their responses by January 20, 2026, at 2:00 PM Eastern, via email to the primary contacts, Jeanette Collins and Julie Burns, whose emails are provided in the opportunity overview. This RFI is for planning purposes only, and no contract will be awarded based on the responses received.
    Analgesic Ketamine for Battlefield Use
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is conducting a Request for Information (RFI) for the development of an analgesic ketamine product intended for battlefield use. This initiative aims to identify industry partners capable of creating a solution for acute severe pain resulting from battlefield injuries, with a focus on products that are suitable for austere, pre-hospital conditions and do not require refrigeration or reconstitution. The desired ketamine formulations may include various delivery methods such as autoinjectors, oral capsules, and topical applications, and must be operable in extreme temperatures with a shelf life of 2-3 years. Interested parties are required to submit a Capabilities Statement by January 12, 2026, detailing their product characteristics, manufacturing capabilities, and FDA approval strategies. For further inquiries, contact Jeanette Collins at jeanette.m.collins4.civ@health.mil or Shannon Lertora at shannon.p.lertora.civ@health.mil.
    Detector Kit, Chemical
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Land Warren, is soliciting proposals for the procurement of 22 units of a Chemical Detector Kit (NSN: 6665-01-706-8739) with an option for an additional 22 units. This firm-fixed price contract requires that the kits conform to specific government drawings and standards, with inspection and acceptance occurring at the origin, necessitating coordination with the Defense Contract Management Agency (DCMA). Proposals must be submitted via email to the primary contact, Patricia M. Roussin, by December 15, 2025, at 11:59 PM EST, and a Technical Data Package is available for interested parties who meet the necessary access requirements.
    Synopsis - M256A2 Chemical Agent Detector Kit
    Dept Of Defense
    The Department of Defense, specifically the U.S. Army Contracting Command – Detroit Arsenal, is preparing to solicit a five-year, firm-fixed price indefinite delivery indefinite quantity contract for the M256A2 Chemical Agent Detector Kit. This procurement aims to acquire an estimated total of 83,653 kits, with a minimum guaranteed quantity of 2,766 kits, essential for detecting chemical agents in various military operations. The solicitation, anticipated to be released within the next two months, will be conducted on a full and open competition basis, and interested parties are encouraged to monitor SAM.gov for updates and amendments. For inquiries, contact Contract Specialist Danielle Campbell at danielle.r.campbell9.civ@army.mil.
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.